Cardiology Pharmaceuticals June 5, 2023
Lexicon’s Lands Long-Awaited HF Approval June 5, 2023
Lexicon Pharmaceuticals’ Inpefa (sotagliflozin) just became the first FDA-approved dual SGLT2 / SGLT1 inhibitor for treating heart failure, landing a wide-ranging approval that could alter the HF treatment arena.
Remote Care June 1, 2023
UCSD’s Wearable Cardiac Ultrasound Milestone June 1, 2023
A team of UCSD scientists took a major step towards changing how, when, and where cardiac ultrasound exams are performed, unveiling the first fully integrated wearable ultrasound system intended for continuous heart monitoring.
Remote Care May 25, 2023
Remote Cardiac Monitoring Gains Momentum May 25, 2023
The last week featured two of the world’s largest heart failure and electrophysiology conferences, each driving a surge of new papers and studies suggesting that remote monitoring is moving to the forefront of both cardiology subspecialties.
Cardiology Pharmaceuticals May 22, 2023
SCOTUS Rules Against Amgen in PCSK9 Patent Dispute May 22, 2023
The U.S. Supreme Court ruled against Amgen in its PCSK9 inhibitor patent dispute with Sanofi and Regeneron that was intended to revive patents for Amgen’s cholesterol-lowering drug, Repatha.
Cardiology Pharmaceuticals May 18, 2023
Amarin Vascepa’s Coronary Physiology Improvements May 18, 2023
Amarin presented results from the latest study on its Vascepa CVD medication (icosapent ethyl, aka IPE), suggesting that IPE improves users' coronary physiology.
Artificial Intelligence May 15, 2023
Philips Expands into Echo AI with DiA Acquisition May 15, 2023
Philips took a major step towards automating and expanding access to echo ultrasound exams, acquiring echo AI startup DiA Imaging Analysis.
Cardiology Pharmaceuticals May 11, 2023
AstraZeneca’s Farxiga Lands Heart Failure FDA Extension May 11, 2023
AstraZeneca’s Farxiga (dapagliflozin) oral SGLT2 inhibitor just landed FDA approval for a far wider range of heart failure patients, now covering risk reduction among all adults with HF -- regardless of their left ventricular ejection fraction status.
Cardiology Pharmaceuticals May 8, 2023
Tirzepatide Delivers in SURMOUNT-2 May 8, 2023
Results from Eli Lilly’s SURMOUNT-2 trial are in, and they further confirmed that its GLP-1 agonist tirzepatide drives meaningful weight loss among obese or overweight adults with type 2 diabetes.
Preventive Cardiology May 4, 2023
Unraveling Depression’s CVD Link May 4, 2023
People with depression have up to 72% higher risks of developing cardiovascular disease, but there’s still many scientific blindspots regarding the links between depression and CVD. Two new studies added visibility to those blindspots, particularly related to prenatal depression and psychotherapy.
Cardiology Pharmaceuticals May 1, 2023
A Case for Antihypertensive Polypills May 1, 2023
A new JAMA Cardiology study suggests that many hypertension patients could benefit from beginning their treatment with “polypills” featuring a combination of three or four low-dose antihypertensives, rather than starting with one or two BP-lowering agents and escalating if they don’t prove effective.
Cardiology Practices April 27, 2023
Cardiovascular Associates Bolsters VBC Capabilities with NovoCardia Acquisition April 27, 2023
Private equity-backed and value-based care-focused cardiology group acquisitions have become an almost weekly occurrence in 2023, but Cardiovascular Associates of America’s (CVAUSA) acquisition of NovoCardia introduced a new telehealth-led angle to this trend.
Artificial Intelligence April 24, 2023
Toku Envisions Retail-Based Retinal CVD and Diabetes Screening April 24, 2023
Cardiovascular disease and diabetes screening might be headed to your neighborhood eyeglasses retailer, at least if retinal AI startup Toku Eyes and its heavyweight optical industry backers prove correct.
Artificial Intelligence April 20, 2023
Cardiology’s AI Optimization Opportunity April 20, 2023
Cardiology AI's downstream potential, delayed and early AF ablation outcomes, and plenty of other cardiology news.
Cardiology Pharmaceuticals April 17, 2023
The Potential of Personalized Hypertension Medicine April 17, 2023
A new study out of Sweden shows that people with hypertension can respond significantly better to some treatments than others, suggesting that hypertension treatment decisions might become far more personalized in the future.
Preventive Cardiology April 13, 2023
Is Moderate Exercise Safe on Statins? April 13, 2023
An interesting new study out of the Netherlands revealed that statins don’t exacerbate muscle-related harms from prolonged moderate-intensity exercise, and statin-associated muscle symptoms (SAMS) shouldn't stand in the way of physical activity.
Cardiac Imaging April 10, 2023
HeartFlow Lands $215M Series F April 10, 2023
Fourteen months after canceling a SPAC deal that would have helped solidify its FFRCT leadership and drive its expansion across the overall CCTA AI segment, HeartFlow landed a $215M Series F round to help make those goals a reality.
Artificial Intelligence April 6, 2023
Echo AI Improves LVEF Workflow and Variability April 6, 2023
Cedars-Sinai researchers published what might be the strongest evidence yet of AI’s ability to improve echocardiography workflows and accuracy.
Surgeries & Interventions April 3, 2023
Long AF Ablation Delays Drive Adverse Events April 3, 2023
A new study out of Canada exposed the country’s long atrial fibrillation ablation wait times, while showing how widespread AF ablation delays can have significant public health consequences.
Surgeries & Interventions March 30, 2023
Procyrion Aortix’s CRS Impact March 30, 2023
Data presented at THT 2023 showed that Procyrion's Aortix pump leads to rapid decongestion and improved kidney function in hospitalized patients with cardiorenal syndrome, representing a key milestone for Procyrion and potentially for CRS treatment.
